Full Text View
Tabular View
No Study Results Posted
Related Studies
Double Blind Study of Trp01 in Patients With Alzheimer's Disease
This study has been completed.
First Received: September 13, 2005   No Changes Posted
Sponsored by: Queen's University
Information provided by: Queen's University
ClinicalTrials.gov Identifier: NCT00202124
  Purpose

The purpose of this study is to determine whether tryptophan is effective in the treatment of mild to moderate Alzheimer's Disease (AD).


Condition Intervention Phase
Alzheimer's Disease
Drug: Tryptophan
Phase IV

Genetics Home Reference related topics: Alzheimer disease
MedlinePlus related topics: Alzheimer's Disease
Drug Information available for: Tryptophan
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Double Blind Medium Term Efficacy Study of Trp01 in Patients With Mild to Moderate Alzheimer's Disease

Further study details as provided by Queen's University:

Primary Outcome Measures:
  • 1. MMSE score
  • 2. Alzheimer’s Disease Assessment Scale, cognitive subpart (ADAS-Cog) as an evaluation of cognitive functioning

Secondary Outcome Measures:
  • 1. Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC)
  • 2. Neuropsychiatric Inventory (NPI)
  • 3. Disability Assessment for Dementia (DAD)
  • 4. Physical Self-Maintenance Scale (PSMS)
  • 5. Functional Activities Questionnaire (FAQ)

Estimated Enrollment: 12
Study Start Date: April 2001
Estimated Study Completion Date: March 2002
Detailed Description:

The clinical trial will be a double-blind, placebo-controlled study with patients being randomized in a 2:1 ratio into groups A and B, respectively:

Group A: TRP01 1g b.i.d. for 26 weeks

Group B: placebo capsules b.i.d. for 26 weeks

After the initial screening, clinic visits will take place at 0, 13 and 26 weeks. The blinding will be maintained until all patients have completed the 26-week trial. Any patients wishing to continue taking the medication upon completion of the trial will be provided a prescription for the drug and may purchase it at their own expense.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients will be selected in order to fulfill both of the following definitions:

  • Dementia according to DSM-IV criteria :

    • development of multiple cognitive deficits manifested by both memory impairment and one or more of the following cognitive disturbances: aphasia, apraxia, agnosia, disturbance in executive functioning
    • the above-mentioned deficits cause significant impairment in social or occupational functioning
    • they do not occur exclusively during the course of delirium
  • Dementia according to communicative disorders and stroke criteria (NINCDS-ADRDA)

    • dementia established clinically and documented by a Folstein Mini-Mental State Examination (MMSE)
    • deficits in two or more areas of cognition
    • progressive worsening of memory and other cognitive functions
    • no disturbance of consciousness
    • absence of systematic disorders or other brain diseases that in and of themselves can account for progressive deficit in memory and cognition

Furthermore, patients must fulfill the following criteria:

  • men, or postmenopausal or surgically sterilized women
  • with severity of dementia of mild to moderate degree as reflected by a score of greater than 14 but less than 26 on the MMSE
  • with a minimum one-year duration of the symptomatology (progressive worsening of memory and other cognitive functions)
  • living at home or in an institution provided that they have reliable caregivers
  • able to perform the required psychometric tests and evaluations. Visual and auditory acuity (with glasses or hearing aid if required) must be sufficient to complete the protocol-specified procedures.
  • Clinical laboratory battery (see section 7.2.2) must yield results within normal limits or determined as not clinically significant by the study physician for the patient’s sex and age
  • Patients and their substitute decision-makers must have signed the written informed consent form

Exclusion Criteria:

Patients with any of the following will not be included in the study:

  • Patients with any other cause of dementia as evidenced by medical history, general physical and neurological examination, laboratory tests, and neuroradiological findings:

    • Vascular dementia, as evidenced by Modified Hachinski Ischemia Scale
    • Depressive pseudementia, as evidenced by cognitive disturbances concomitant to a major depressive episode according to DSM-IV and/or a history of more than one major depressive episode
    • DSM-IV criteria for any major psychiatric disorder including schizophrenia, alcohol or substance abuse
    • Huntington’s chorea or Parkinson’s disease, evidenced by neurological examination, with an onset prior to or concurrent with dementia
    • Creutzfeldt-Jakob disease
    • Intracranial mass lesion
    • Clinically important head injury
    • History or current evidence of stroke
    • Onset of dementia following cardiac arrest or heart surgery
    • Neurosyphilis
    • Seropositivity for HIV
    • Vitamin B12 deficiency
    • Uncorrected hypothyroidism (i.e. abnormal free T4, ultrasensitive TSH)
  • Patients with other relevant concomitant diseases:

    • Patients with history or current evidence of a sleep disorder
    • Patients with a clinically significant cardiovascular, renal, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, opthalmologic, or hematologic condition
    • Current evidence or history within the past year of myocardial infarction (MI), congestive heart failure
    • Blood pressure at screening of > 180 mm Hg systolic or 100 mm Hg diastolic
    • Impaired renal, hepatic, or gastrointestinal function, which could interfere with drug absorption, metabolism or excretion
    • Seizure disorder
    • Diabetes
    • Earlier diagnosis or current evidence of cataracts
    • Progressive fatal disease (other than AD)
    • Treatment with any other investigational drug in the last 8 weeks prior to screening
    • Previous administration of TRP01
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00202124

Locations
Canada, Ontario
Queen's University
Kingston, Ontario, Canada, K7L 3N6
Sponsors and Collaborators
Queen's University
Investigators
Study Chair: Donald F Weaver, MD, PhD Queen's University
  More Information

No publications provided

Study ID Numbers: DFW-TRP01
Study First Received: September 13, 2005
Last Updated: September 13, 2005
ClinicalTrials.gov Identifier: NCT00202124     History of Changes
Health Authority: Canada: Health Canada

Study placed in the following topic categories:
Tryptophan
Alzheimer Disease
Psychotropic Drugs
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Dementia
Antidepressive Agents, Second-Generation
Antidepressive Agents
Delirium

Additional relevant MeSH terms:
Tryptophan
Alzheimer Disease
Nervous System Diseases
Psychotropic Drugs
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Pharmacologic Actions
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Therapeutic Uses
Dementia
Tauopathies
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on May 07, 2009